Answers are grounded in this paper and cite their sources.
How does the flagship journal of a scientific society contribute to celebrating said society's birthday? This question was discussed for the first time a year ago by the editorial team of Clinical Pharmacology & Therapeutics (CPT) in anticipation of the 2025 American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting, which will mark its 125th anniversary.1, 2 We decided to mark this milestone with a special themed issue of CPT, encapsulating the evolution of clinical pharmacology and its critical role in translating scientific innovations to novel therapies (Figure 1). Of course, we could have done this in various ways, but we settled on the idea to reprint the most highly cited original research article from each decade since the launch of CPT ~ 60 years ago, each with an accompanying Commentary on the importance of the work (Table 1). We believe the result is a unique whistle-stop tour of landmark papers that have defined our discipline and are the foundation for where it is today. As a reviewer noted of one of the commentary/historical article pairs, “I think that every PharmD and graduate student in the pharmacy school should have this commentary on their reading list.” In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis and the Effect-Compartment Model6 Role of Intestinal P-Glycoprotein (mdrl) in Interpatient Variation in the Oral Bioavailability of Cyclosporine7 Identification of Functionally Variant MDR1 Alleles Among European Americans and African Americans9 Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-positive Lesions in Patients with metastatic breast Cancer11 The Approved Dose of Ivermectin Alone is Not the ideal Dose for the Treatment of COVID-1913 Trust, Transparency, and Translation: How Clinical Pharmacologists Can Strengthen Public Confidence in Pandemic Responses14 It starts with one of the first clinical studies of ketamine six decades ago3, 4 and the classic work by Sheiner et al.5, which became the foundation of what is now known as pharmacometrics and model-informed drug development (MIDD) in the 1970s.6 Next, our overview highlights the seminal work that helped to define the critical role of transporters in the 1990's,7-10 and subsequently the first papers on the clinical pharmacology of novel targeted cancer therapies at the beginning of this century.11, 12 Perhaps unsurprisingly, the paper that defined the current decade—based on our criteria of highest number of citations—was related to the role of clinical pharmacology in the COVID pandemic.13, 14 The paper “A method for estimating the probability of adverse drug reactions” by Naranjo et al.,15 which represents the 1980s decade, deserves a special mention since it is the most highly-cited CPT paper of all time. We were honored that two co-authors of the original work, Drs Greenblatt and Sellers, were willing to share their personal reflections on their seminal article.16 Selecting only seven papers does not do justice to the many other great works CPT has published over the decades, and restricting our selected articles to original research further narrowed our scope. Therefore, we have created a special virtual issue that includes the 15 most-cited articles from each decade. You can find this at CPT's homepage (https://ascpt.onlinelibrary.wiley.com/journal/15326535) on the “Anniversary Issue” tab. The articles are also broken out by decade and provide an even more complete portrait of the research CPT has published through the years. CPT is only one part of the ASCPT journal family, and thus it is also worth noting the contributions of CPT's sister journals, CPT: Pharmacometrics & Systems Pharmacology (PSP) and Clinical and Translational Science (CTS). PSP was launched in 2012 as a journal devoted to publishing advances in quantitative, model-based approaches as applied in pharmacology, (patho)physiology, and disease to aid the discovery, development, and utilization of human therapeutics. PSP continues to emphasize the application of modeling, and it regularly publishes Tutorials that provide step-by-step instructions to users for the technical, scientific, and strategic implementation of MIDD approaches. These tutorials provide practical guidance of use to clinicians, scientists, and students worldwide. ASCPT acquired CTS in 2015, and that journal has become the beacon for the field of translational science, highlighting original research that bridges laboratory discoveries with the diagnosis and treatment of human disease. Its recently launched article series of Mechanism of Action Mini Reviews aptly illustrates this commitment; each article aims to demystify these complex therapeutics, from mechanism to development and regulatory journey to clinical impact. For clinicians, pharmacists, and researchers, these mini reviews offer a concise understanding of new therapeutics. For patients and the general public, they provide insights into how these drugs can manage or cure diseases, enhancing informed healthcare decisions. Of course, a scientific society is vastly more than its journals. For 125 years, ASCPT has advanced the science of clinical pharmacology, fostered relationships among its members, provided career and networking opportunities, and advocated for scientific rigor, all with a goal of improving patient care. This year's Annual Meeting, “Patient-Centric Clinical Pharmacology,” is a prime example of all the above. And while much about the 2025 Annual Meeting—scientific panels, question-and-answer sessions, breaktime networking—would look familiar to members from the earliest days of the Society, there is much about the meeting that might be less familiar—from the diversity of the members and speakers to the technology-enabled meeting formats and, perhaps most of all, the advances in the science over 125 years. To reach a 125th anniversary, scientific societies must adapt and change with the times, while maintaining a core set of strengths and values. The founding members of 1900 could not have imagined an online learning platform that would allow members to continue to present science year-round, and for other members from across the globe to access the presentations from their office (or from their backyard if they choose). The term “webinar” would be wholly unfamiliar to them, but they would understand a “seminar” and enjoy the ability to engage with colleagues and topics of interest on a regular basis. While adopting new technology is important, even more so is engaging young scientists. Ensuring they have a place in ASCPT is a key component of welcoming new ideas and perspectives, while also instilling our newest members with a sense of the Society's history and core values. ASCPT's Leadership Accelerator aims to do just this. In this issue,2 the members of the inaugural Leadership Accelerator cohort share their perspective on this and other ASCPT initiatives to welcome new members. As they write, the Leadership Accelerator “immerses participants in ASCPT's governance, educational initiatives, and strategic priorities while offering mentorship from distinguished Society leaders.” This, along with other initiatives such as the journals' Editor-in-Training program, and the Student/Trainee and Early Career communities, allows for the Society to continue to grow and adapt. ASCPT's recently launched Low and Middle Income (LMIC) Accelerator offers scientists from around the globe the opportunity to engage with ASCPT through mentorship and full participation in the Society, including a travel grant to attend the Annual Meeting. To remain true to our core principles and values, it is important to understand the Society's history. ASCPT's CEO, Abigail Gorman, and current and incoming Presidents, Matthew Rizk and Sandra Visser, share more details about the Society,1 and reflect on its past, present, and future. They note, “Throughout its history, ASCPT has upheld core values of scientific rigor, community, and a commitment to improving patient care. These principles have guided the Society through scientific revolutions, societal challenges, and global crises, enabling it to adapt, lead, and advance.” They provide valuable insights on where the Society has been and where it is going. Their leadership, along with the contributions of many long-term members and the new perspectives of our youngest members, should give everyone great confidence in the next 125 years for ASCPT. It is impossible to know what CPT's Editor-in-Chief and Managing Editor might write upon ASCPT's 250th anniversary in 2150. The new technologies they will have access to are as difficult for us to fathom as a Zoom meeting would have been for a member in 1900. The scientific advancements our members will be a part of will improve patients' lives in ways we can't foresee. We believe at least 125 more years of great science are ahead, and what our members research, study, collaborate on, and share with the world will be truly exciting! No funding was received for this work.
No takes yet. Share an insight, caveat, or question.
Graaf et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: